Sign In
Buy VAXX
$0.0001
+0 (+0%)
At Close: Jun 03, 2026
Vaxxinity (NASDAQ:VAXX) and Evotec (OTCMKTS:EVTCY) Head to Head Comparison
03:18am, Thursday, 26'th Feb 2026
Profitability This table compares Vaxxinity and Evotec's net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Vaxxinity N/A N/A N/A Evotec 20.85% 16.02% 7.
Critical Review: iBio (NYSE:IBIO) versus Vaxxinity (NASDAQ:VAXX)
01:26am, Tuesday, 24'th Feb 2026
Vaxxinity (NASDAQ: VAXX - Get Free Report) and iBio (NYSE: IBIO - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the
Congress makes $4.5 trading stocks in a day; Here's the biggest winners
06:36am, Thursday, 04'th Jul 2024
Though it isn't unheard of for a member of Congress to have not traded any stocks after getting elected while supporting tighter regulations for politicians' equities market activity, the House and th
Vaxxinity UB-312 Parkinson's Trial Results Published in Nature Medicine
06:00am, Thursday, 20'th Jun 2024
UB-312 is the first Parkinson's candidate to reduce pathology as measured by a seed amplification assay, and suggest clinical improvement on motor experiences of daily living.
Why Is Vaxxinity (VAXX) Stock Up 39% Today?
08:24am, Friday, 03'rd May 2024
Vaxxinity (NASDAQ: VAXX ) stock is up on Friday with heavy pre-market trading of the biotechnology company's shares. That has more than 21 million shares of VAXX stock changing hands as of this writi
Why Is Vaxxinity (VAXX) Stock Down 58% Today?
08:40am, Monday, 22'nd Apr 2024
Vaxxinity (NASDAQ: VAXX ) stock is falling hard on Monday after the biotechnology company announced plans to voluntarily delist its shares from the Nasdaq Exchange. Vaxxinity will file to delist its
Vaxxinity Issues Shareholder Letter
06:53pm, Friday, 19'th Apr 2024
CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new
Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock
04:27pm, Friday, 19'th Apr 2024
CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting
09:23am, Thursday, 28'th Mar 2024
Presentation will address the Company's clinical data in Parkinson's disease Presentation will address the Company's clinical data in Parkinson's disease
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates
04:41pm, Wednesday, 27'th Mar 2024
CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financia
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024
10:32am, Thursday, 07'th Mar 2024
UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson's patients UB-312 is first immunotherapy to show reduction of pathological alpha-syn
Vaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
08:00am, Thursday, 15'th Feb 2024
Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys.
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024
08:00am, Tuesday, 13'th Feb 2024
CAPE CANAVERAL, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida
08:00am, Tuesday, 30'th Jan 2024
CAPE CANAVERAL, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a research collaboration
Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida
08:00am, Thursday, 18'th Jan 2024
CAPE CANAVERAL, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today announced a collaboration with the
